MK-5172 reduced HCV RNA in stable replicon assays. Potency varied with genotype, serum condition and variant; the A156T result and the serum-associated EC50 shift limit broad potency generalizations. [1]
In engineered mammalian cells, grazoprevir selectively redirected NS3a toward the GNCR1 reader at the plasma membrane. This chemical-control application required introduced fusion proteins. [2]
NS3/4A protease inhibition across the tested enzyme panel
Biochemical assay · Recombinant HCV NS3/4A proteases from genotypes 1a, 1b, 2a, 2b and 3a, with separately assayed genotype 1b variants. [1]
MK-5172 inhibited the tested baseline enzymes at subnanomolar Ki values. Activity was weaker against A156T and A156V. Vaniprevir, danoprevir and TMC435 were parallel reference inhibitors in Table 1.
Literature-Reported Treatment Conditions
- Method
- Biochemical protease inhibition with time-resolved fluorescence detection.
- Co-treatment
- None; reference inhibitors were tested separately.
- Reported limits
- The acquired main article does not specify Table 1 assay incubation time, concentration series, vehicle or replicate n. Referenced assay protocols were not retrieved; no conditions borrowed.
Methods and source locations
Compound reported in the paper: Grazoprevir; Compound label in the paper: MK-5172
Inhibition of the assayed NS3/4A proteases; no claim that all variants remain equally sensitive.
Results, In vitro activity and selectivity; Table 1 and footnote a; Materials and Methods, Compound and initial In vitro assays paragraph
Protease inhibition in baseline genotype enzymes; means ± SD: Time-resolved fluorescence protease assay; Table 1 values, not treatment concentrations. — Table 1, MK-5172 column, baseline genotype rows; footnote a
Reduced potency against two genotype 1b variants; means ± SD: Same comparative enzymatic panel; both unfavorable results retained. — Table 1, gt1b A156T and A156V rows; footnote a
Cell-based potency, serum shift and cytotoxicity
Cell-based study · Stable HCV replicon cell lines: gt1b con1 (HB1), gt1a and gt2a; Table 2 includes genotype 1b variant lines. [1]
Cell-based activity depended on genotype, serum condition and variant. The gt1b con1 EC50 increased in 40% normal human serum, and A156T was less sensitive. The cytotoxicity threshold exceeded the tested antiviral EC50 values.
Literature-Reported Treatment Conditions
- Method
- Separate concentration-response assessments of RNA reduction and cell viability.
- Co-treatment
- MK-5172 alone.
- Reported limits
- Table 2 exposure duration, concentration series, replicate n and vehicle are not specified in the acquired main-text assay description. The gt1a line identifier is not given there. Referenced protocols were not retrieved.
Methods and source locations
Compound reported in the paper: Grazoprevir; Compound label in the paper: MK-5172
Cell-based assay endpoints only. EC50 and CC50 are assay outcomes, not recommended treatment doses.
Results, In vitro activity and selectivity; Table 2 and footnote a; Materials and Methods, initial In vitro assays paragraph
Cell-based HCV RNA endpoint; means ± SD: TaqMan-based replicon potency assay; routine serum condition described as 10% FBS. — Table 2 baseline genotype rows and footnote a; initial In vitro assays paragraph
gt1b con1 potency in 40% normal human serum; mean ± SD: Separate serum condition within the same Table 2 panel; not a clinical exposure target. — Table 2, gt1b con1 40% NHS row; footnote a
gt1b A156T cell-based potency; mean ± SD: Same stable-replicon panel; unfavorable variant result. — Table 2, gt1b A156T row; footnote a
Replicon-cell cytotoxicity; footnote identifies CC50 as mean only: MTS viability assay (Cell Titer Aqueous One); no SD supplied for CC50. — Table 2, CC50 row and footnote a; initial In vitro assays paragraph
Selective grazoprevir-dependent colocalization in engineered mammalian cells
Cell-based study · Engineered NIH3T3 (Flp-In-3T3) cells expressing NS3aH1-mCherry, plasma-membrane GNCR1-BFP-CAAX and mitochondrial Tom20-DNCR2-EGFP. [2]
Grazoprevir promoted NS3a colocalization with plasma-membrane GNCR1; danoprevir instead promoted mitochondrial DNCR2 colocalization. DMSO controls were included. The separate Figure 2b specificity experiment showed that grazoprevir did not recruit DNCR2 to mitochondrial NS3a.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM grazoprevir (Figure 2c); 10 μM grazoprevir (Figure 2b).
- Exposure duration
- 15 minutes for the three-color Figure 2c experiment; 1 hour for Figure 2b.
- Method
- Drug treatment followed by fixation and confocal colocalization analysis.
- Vehicle
- Equal-volume DMSO controls; final DMSO percentage not specified in the read methods.
- Co-treatment
- Engineered NS3a/reader fusion proteins required; danoprevir and asunaprevir were separate comparator treatments.
- Reported limits
- Cell counts and P values are assigned to Supplementary Table 3, which was not retrieved. No exact correlation values or significance claims extracted.
Methods and source locations
Compound reported in the paper: Grazoprevir; Compound label in the paper: Grazoprevir
A research application as a chemical input in an engineered protein system; no endogenous trafficking or antiviral efficacy claim.
Results, Validation of PROCISiR in mammalian cells; Figure 2b–c and caption; Online Methods, Inhibitor sources and Confocal microscopy for fluorescent protein colocalization analysis
NS3a/reader colocalization at the plasma membrane versus mitochondria: Confocal microscopy and ImageJ Pearson correlation analysis; figure direction assessed visually without digitizing coefficients. — Figure 2c, schematic and colocalization distributions; Results S3; Online Methods S24
Negative specificity control for DNCR2-mediated mitochondrial recruitment: Figure 2b drug-specificity comparison with DMSO and asunaprevir controls. — Figure 2b and caption; Results S3; Online Methods S24